Selecta/Sobi Gout Drug Numerically, Not Significantly, Beat Krystexxa
SEL-212 Bested Horizon’s Drug But A New Standard Is Emerging
Executive Summary
Analysts have mixed opinions about whether a Phase IIb study of SEL-212, which Selecta recently licensed to Sobi, helps the drug’s commercial potential versus Horizon’s Krystexxa.
You may also be interested in...
Phase III Results Position Selecta/Sobi’s SEL-212 As Tough Competition For Krystexxa In Gout
Analysts pointed to SEL-212’s more favorable dosing and adverse event profile with fewer limitations that may harm compliance versus Krystexxa from Horizon, which is soon to be acquired by Amgen.
Sobi Loses Private Equity Buyout
An $8bn public-to-private takeout by two private equity firms of the Swedish rare disease specialist collapses because total tenders to the offer fell below a 90% threshold.
Sobi To Go Private In $8.1bn Buyout That Appreciates Growth Strategy
Agnafit Bidco, comprised of Advent International and an affiliate of GIC Pte Ltd, will pay a premium for the rare disease specialist in an effort to capture value from Sobi’s planned growth.